Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer

被引：0
|
作者：
Shtivelband, Mikhail
Spigel, David R.
Gerber, David E.
Jain, Minish Mahendra
Ponomarova, Olga V.
Giorgadze, Davit
Shan, Joseph
Menander, Kerstin B.
Belani, Chandra Prakash
机构：
[1] Ironwood Canc & Res Ctr, Chandler, AZ USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] UT Southwestern Med Ctr, Dallas, TX USA
[4] Ruby Hall Clin, Pune, Maharashtra, India
[5] RE Kavetsky Inst Expt Pathol Oncol & Radiobiol, Kiev, Ukraine
[6] Chemotherapy & Immunotherapy Clin, Tbilisi, Georgia
[7] Peregrine Pharmaceut Inc, Tustin, CA USA
[8] Penn State Hershey Canc Inst, Hershey, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8095
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
    Serke, M
    Schoenfeld, N
    Loddenkemper, R
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
  • [2] Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study
    G. Robinet
    F. Barlesi
    P. Fournel
    H. Berard
    R. Corre
    A. Vergnenegre
    L. Falchero
    P-J. Souquet
    A. Tisseron-Carrasco
    C. Chouaid
    Targeted Oncology, 2007, 2 : 63 - 71
  • [3] Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study
    Robinet, G.
    Barlesi, F.
    Fournel, P.
    Berard, H.
    Corre, R.
    Vergnenegre, A.
    Falchero, L.
    Souquet, P-J.
    Tisseron-Carrasco, A.
    Chouaid, C.
    TARGETED ONCOLOGY, 2007, 2 (02) : 63 - 71
  • [4] A randomised phase II study of pemetrexed versus pemetrexed plus erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
    Dittrich, Christian
    Papai-Szekely, Zsolt
    Vinolas, Nuria
    Sederholm, Christer
    Hartmann, Joerg T.
    Behringer, Dirk
    Kazeem, Gbenga
    Desaiah, Durisala
    Leschinger, Monika I.
    von Pawel, Joachim
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (09) : 1571 - 1580
  • [5] Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study
    Rossi, D
    Graziano, F
    Ugolini, M
    Dennetta, D
    Alessandroni, P
    Catalano, V
    Giordani, P
    Fedeli, SL
    Fedeli, A
    Catalano, G
    TUMORI JOURNAL, 2004, 90 (01): : 50 - 53
  • [6] Second-line envafolimab and beyond in locally advanced or metastatic non-small cell lung cancer
    Guan, M.
    Shi, Q.
    ANNALS OF ONCOLOGY, 2024, 35
  • [7] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [8] Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer
    Huber, R
    Schmidt, M
    Borgmeier, A
    LUNG CANCER, 2005, 49 : S248 - S248
  • [9] Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
    Gerber, D. F.
    Horn, L.
    Boyer, M.
    Sanborn, R.
    Natale, R.
    Palmero, R.
    Bidoli, P.
    Bondarenko, I.
    Germonpre, P.
    Ghizdavescu, D.
    Kotsakis, A.
    Lena, H.
    Losonczy, G.
    Park, K.
    Su, W-C
    Tang, M.
    Lai, J.
    Kallinteris, N. L.
    Shan, J. S.
    Reck, M.
    Spigel, D. R.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1548 - 1553
  • [10] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    LUNG CANCER, 2009, 64 : S13 - S13
12345